Pharmafile Logo
Pharmafocus logo
Advanced Search

lacosamide

Showing 3 posts of 3 posts found.

ucb_logo_pole2

US court rules in favour of UCB in patent dispute, shares jump

August 16, 2016
Manufacturing and Production, Research and Development, Sales and Marketing UCB, lacosamide, patent, vimpat

UCB has received a major boost after a Delaware district court confirmed the validity of the company’s patents on one …

News

UCB plots new Vimpat submissions after positive monotherapy results

October 8, 2015
Research and Development EMA, European Medicines Agency, UCB, carbamazepine, epilepsy, lacosamide, phase III, vimpat

A Phase III non-inferiority study comparing UCB’s Vimpat with carbamazepine suggests the two drugs can be used as monotherapy treatments.  …

News

UCB sponsors ‘Hack Epilepsy’ digital event

March 12, 2015
Medical Communications, Sales and Marketing Keppra, UCB, epilepsy, hack, lacosamide, levetiracetam, vimpat

Belgian biopharma firm UCB says it will be sponsoring a ‘Hack Epilepsy’ event this year to help support patient needs …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026